Popular Articles

Early Switch From Cyclosporine To Sirolimus After Renal Transplantation Produces Sustained Improvement In Renal Function
BOSTON - Favorable 12-month outcomes are maintained through 30 months of follow-up when renal transplant patients are converted from a cyclosporine (CsA)-based regimen to a sirolimus (SRL)-based regimen three months post-transplant, according to results of the CONCEPT study announced here at the American Transplant Congress (ATC) 2009.

Warning On Untreated Bitter Lupins After Two Women Become Ill, Australia
Consumers should be warned about the dangers of eating untreated bitter lupin beans after two people who consumed products containing the beans became ill with anticholinergic syndrome, according to an article in the Medical Journal of Australia.
News of the day
Greater Boston Unites To Transform Health Care
A coalition of organizations representing healthcare stakeholders throughout Greater Boston has been selected by the Robert Wood Johnson Foundation (RWJF) to participate in a planning grant to become part of the Aligning Forces for Quality (AF4Q) initiative. AF4Q is the Foundation"s signature effort to lift the overall quality of healthcare in targeted communities, reduce racial and ethnic disparities, and provide models for national reform.
Diagnostics

Sol-Gel Anti-Acne Clinical Study Shows Significantly Improved Efficacy And Safety

Sol-Gel Technologies Ltd, a specialty pharmaceuticals company, announced today results from a comparative clinical study. The results demonstrate that the company"s two strength Anti-Acne kits achieved pronounced efficacy and markedly improved tolerability. The study will be presented at the 10th International Congress of Dermatology in Prague, May 20-23, 2009. "As early as week two we noted a very early reduction of acne lesions, which was significantly superior to leading commercial products, and at week four a 75 percent improvement was achieved," said Stanley Shapiro, PhD, Head of Sol-Gel"s Skin Care Science & Technology unit. "Throughout the study Sol-Gel"s high-strength kits were significantly better tolerated than the two commercial products." The Sol-Gel Anti-Acne kits feature Sol-Gel"s patented drug delivery technology. "In the Sol-Gel kits, the proprietary silica microcapsules encase and continuously release the benzoyl peroxide, enabling a significant increase in efficacy and tolerance in comparison to products containing free benzoyl peroxide," said Ofer Toledano, PhD, VP, Research and Development. The principles of the Sol-Gel encapsulation system will also be presented at the Dermatology Congress. Study Methodology Participants in the double-blind, controlled and randomized, 4-week, 4-arm parallel groups were randomized to receive one of Sol-Gel"s kits or of a comparable leading commercial products. Safety and tolerability were assessed by the Principal Investigator dermatologist who also evaluated the rates and grades of erythema, edema, dryness, scaling/peeling, stinging/burning, itching and skin tightness. Efficacy was assessed by lesions count, including total lesions count, inflammatory and non-inflammatory lesions and Investigator Global Assessment by improvement of Severity Score. Sol-Gel"s Anti-Acne Kits Sol-Gel"s Anti-Acne kits provide a fast-acting, highly-effective and well-tolerated benzoyl peroxide-based acne care program. In contrast to other treatments, the kits deliver visible reduction of acne as quickly as within three days and after two weeks significantly out-perform the leading brand in the resolution of acne and remain substantially more effective with continued use. The Kits, available in two strengths, both treat and prevent acne. Starting with the cleanser, toner and lotion, and optionally adding a spot treatment, the Sol-Gel regimens include timed-release benzoyl peroxide in combination with ingredients that clean, heal and balance the skin. They treat the entire face to reveal clear, blemish-free skin faster - without the dryness and skin irritation caused by other acne treatments. Sol-Gel Technologies


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):